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Summary
This review discusses recent advances in understanding of
the structure and function of the insulin receptor and insulin
action, and how these relate to the clinical aspects of insulin
resistance associated with non-insulin-dependent diabetes
and other disorders. Improved understanding of the molecular
basis of insulin resistance could ultimately lead to a better
understanding of the causation of these conditions and the
design of rational therapy to ameliorate them. Here, particular
attention is devoted to the initial events that follow the binding
of insulin to its receptor, including changes in insulin receptor
phosphorylation. Receptor-mediated insulin resistance may
be a consequence of various factors including increased
serine/threonine phosphorylation of the receptor with de-
creased tyrosine phosphorylation, receptor densitisation,
auto-antibodies to the receptor and inherited structural defects
in the insulin receptor. Defects in insulin action could also
arise at post-receptor events particularly glucose transport.
Other circulating hormones, such as the newly characterised
islet amyloid polypeptide (amylin), may also cause insulin
resistance.
S Atr Med J 1991; 79: 607-613.
A major abnormality in non-insulin-dependent diabetes
(NIDDM) and some rare genetic syndromes is insulin resis-
tance. Insulin is the principal hormone controlling blood
glucose, and it achieves this function by interacting with
specific receptors on cell surfaces mainly in liver, muscle and
adipose tissue. The presence of insulin resistance in patients
implies that a defect is present somewhere along the line of
insulin action from receptor to the alteration of blood glucose.
Hence, in order to elucidate the nature of this defect in
diabetes mellitus, it is important to study the actions of insulin
in vitro and in vivo. Because the binding of insulin to its
receptor is the first step in the action of insulin, it is appropriate
that we should attempt to understand the structure, function
and regulation of the insulin receptor in our efforts to unravel
the cause of this resistance to insulin. The insulin field is
notable for its scientific landmarks over the last 6 decades.
Insulin was among the first peptide hormones to be isolated; I
the first protein to have its amino acid sequence determined;2
the first peptide hormone to have its three-dimensional struc-
ture determined3 and its gene cloned.4 The insulin receptor
was among the first peptide hormone receptors to be charac-
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terised and purified. 5 Despite these intensive efforts by many
investigators, the molecular basis of insulin action remains
largely a mystery in comparison with other hormone receptor
systems. Research has been hampered by the temporally and
biochemically divergent nature of the cellular events that
follow the high-affinity binding of insulin to specific cell
surface receptors in its principal target tissues. Very few of
these events can be explained or unified by any of the well-
defined mechanisms of signal transduction.
Structure, function and regulation of the
insulin receptor
Initial biochemical studies showed that the insulin receptor is
an integral membrane glycoprotein composed of two subunits,
a and 13, linked to form a heterotetrameric f3-a-a-f3 complex.6
The f3-subunit has intrinsic insulin-stimulated tyrosine kinase
activity. 7 These f"mdings were cOnlrrmed by the cloning of the
complementary DNA (cDNA) and the consequent deduced
amino acid sequence.8•9 The insulin receptor gene is located on
chromosome 19, spans more than 120 kilobases and has 22
exons (coding regions) interrupted by introns (intervening,
non-coding sequences) of variable length. IQ Some of the exons
code for discrete functional units (Fig. I). The insulin receptor
is synthesised as single polypeptide precursor that is pre-
destined to form the mature receptor subunits, a and 13 (Fig.
1). The precursor is cleaved by processing enzymes to form
two subunits, the 135 kD a subunit and a 95 kD f3-subunit.
These subunits are then assembled into a mature tetrameric
complex linked by disulphide bonds and inserted into cell
surface membranes (Fig. 1, Fig. 2). The a-subunits are located
extracellularly and most of the f3-subunits are intracellular.
The a-subunit has a cysteine-rich domain (residues 155-312)
that is also seen in the EGF (epidermal growth factor), IGF-I
(insulin-like growth factor I) and LDL (low-density lipo-
protein) receptors. 8•9 It exists as two isoforms that differ in the
presence/absence of a 12-arnino acid insert (Ebina8 extension)
(residues 718-729 according to the sequence of Ebina et a/. 8
owing to alternative splicing of the insulin receptor mRNA
transcript. Insulin binds to the a-subunit and triggers a
conformational change that causes the f3-subunit to autophos-
phorylate on tyrosine residues (Fig. 3). Several regions on the
a-subunit have been implicated in the formation of the insulin
binding site: (I) a region encoded for by exon 2 (residues 7-
190) with phenylalanine 89 being necessary for high-aff"mity
binding,11 and (il) residues 242-247 in the cysteine-rich
domain. 12 The f3-subunit has features in common with other
~rosi~e kinase o~co~enes and serine/threonine rrotein kinases
mcluding ATP-bmdmg and catalytic domains..9 The insulin
receptor is closely related to the IGF-I (somatomedin-C)
receptor in its overall structural organisation, amino acid
sequence and function. 13 The growth-promoting effects of
insulin may be mediated by the IGF-I receptor. Autophospho-
rylation of the f3-subunit activates the receptor towards
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INSULIN PAORECEPTOA
ettects of insulin
Regulation of the insulin receptor by
serine/threonine phosphorylation
What is the function of the second phosphorylation reaction
(serine/threonine) that occurs on the insulin receptor? No
functional effects of this reaction have been demonsmited, but
in other situations increased serine/threonine phosphorylation
in response to activators of other serine/threonine kinases
results in an attenuation of the tyrosine autophosphorylation
and the tyrosine kinase activity. For example, the tumour-
Insulin receptor
a
Fig. 3. Insulin-stimulated phosphorylation of the insulin receptor.
The binding of insulin to the ",-subunit stimulates the phosphory·
lation of the f3-subunit on tyrosine' residues. In intact cells,
tyrosine autophosphorylation of the f3-subunit is followed by
phosphorylation of the f3-sub!!nit on serine/threonine residues in
the C-terminus. This serine/threonine phosphorylation is mediated
by a closely associated enzyme, the insulin receptor serine
kinase (IRSK).
~lnSUlin
Transmembrane signalling and insulin
, receptor phosphorylation
Two major hypotheses are commonly invoked to explain the
nature of insulin receptor signalling. Firstly, the initiation of a
phosphorylation/dephosphorylation cascade by the receptor
kinase with the participation of various kinases and/or phos-
phatases. Alternatively or concurrently, alteration of receptor
conformation-by autophosphotylation to a state that facilitates
its non-eovalent interaction with other effector systems and/or
generates a second messenger17 in a manner reminiscent of
cyclic nucleotides. These distiner pathways could either diverge
or act synergistically to co-ordinate cellular responses.
The rapid insulin-stimulated autophosphorylation of the
insulin r~~~~:or on tyrosine residues 1158, 1162~ 1163, 1328
and 1344 - IS followed by a slower phosphorylatIon on serine
and threonine residues of the C-terminus, particularly serines
1305, 1306 and threonine 134821 - 23 (Fig. 3). This second
serine/threonine phosphorylation reaction is mediated by
another distiner protein kinase, an insulin-activated receptor
serine kinase (IRSK),22,23 that is closely associated with the
insulin receptor. The activation of the IRSK is dependent
upon the initial tyrosine autophosphorylation and hence it has
been hypothesised that the insulin receptor ciirectly phospho-
rylates the IRSK on tyrosine. This leads to activation of IRSK
and the IRSK phosphotylates the insulin receptor in a 'retro-
grade' manner. It is known that insulin action is associated
with the changes in serine phosphorylation of a number of
cellular proteins and hence this IRSK may also then initiate a
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Fig. 1. Biosynthesis of the insulin receptor. Like insulin, the
receptor is synthesised as a single polypeptide precursor, the
proreceptor. The proreceptor is then cleaved into a- and f3-
subunits and assembled to form the minimal functional unit, the
heterotetramer. Some of the exons of the insulin receptor gene
code for discrete functional units. Exon 11 may be spliced out
from messenger RNA to generate two insulin receptor isoforms
that differ only in the presence or absence of the region coded
for by exon 11.
phosphorylating other substrates. 14 The events linking this
autophosphorylation reaction with the eventual cellular effects
of insulin are somewhat obscure and the subject of intensive
research. Evidence derived from genetically engineered mutant
receptors suggests that the tyrosine kinase activity and auto-
phosphorylation of the receptor are important for insulin
action. Removal of the ATP-binding site or some of the major
autophosphorylation sites by site-directed mutagenesis abolishes
most of the effects of insulin_ 15,16
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Fig. 2. Schematic model of the insulin receptor. The 3-D structure
of the receptor is as yet unknown and hence this model is highly
idealised. The' receptor is represented as a heterotetrameric
complex. The a-subunit is located extracellularly. The f3-subunit
traverses the cell membrane with most of the f3-subunit being
located intracellularly. Both a- and f3-subunits are substantially
glycosylated in their extracellular portions. The juxtamembrane
region (Arg-Lys-Arg) may function in signal transduction by
interacting with phospholipids.
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Fig. 4. Cellular effects of insulin. In addition to stimulating phos-
phorylation of the insulin receptor, insulin also provokes changes
in the phosphorylation states of numerous intracellular enzymes.
The translocation of glucose transporter vesicles to the cell
surface may also be a phosphorylation-linked process. Other
effects include the lowering of cyclic AMP levels via the activation
of phosphodiesterases (PDE) and the generation of inositol phos-
phoglycan (IPG) mediators and diacylglycerol (DAG) from the
glycosylphosphatidylinositol (glycosyl-PI) anchor. For simplicity
the anchor is positioned on the inside of the cell. The inositol
glycan mediator affects the activities of several enzymes including
puruvate dehydrogenase, adenylate cyclase and acetyl-coA car-
boxylase. Over a longer period insulin also modulates nucleic
acid synthesis, protein synthesis and cell growth.
intolerance. Cellular mechanisms of insulin resistance in these
conditions are unclear owing to the fact that they have not
been investigated in depth in patients or in cellular models.
Target tissue defects may arise at the receptor-binding phase
or the post-binding phase of insulin action.
promoting phorbol esters that activate protein kinase C result
in increased serine/threonine phosphorylation of the insulin
receptor with accompanying decreases in tyrosine phosphoryla-
tion and kinase activity.24 When cellular levels of protein
kinase C are decreased a potentiation of the insulin-stimulated
tyrosine autophosphorylation occurs, suggesting that protein
kinase C exerts a tonic inhibitory effect on the insulin
receptor. 25 Furthermore, elevation of intracellular cyclic AMP,
which stimulates the cyclic AMP-dependent protein kinase,
also results in increased serine/threonine phosphorylation with
a diminution of the tyrosine autophosphorylation. 26 These
studies imply that the phosphorylation of the insulin receptor
on serine/threonine residues may be a mechanism for negatively
modulating the insulin receptor and consequently may be a
mechanism of insulin resistance. By inference then, the
insuliI).-stimulated serine/threonine phosphorylation by the
IRSK is possibly a negative feedback mechanism whereby
other receptors may be prevented from undergoing further
activation. In this way, it is possible that the insulin receptor,
in common with the f3-adrenergic receptor,27 limits its own
signal transduction by simultaneously activating a receptor-
specific serine/threonine kinase.
Cellular effects of insulin
How do the effects of insulin manifest? (for a review see
references 28, 29, 30). The initial events (within seconds)
include autophosphorylation of the receptor f3-subunit with
activation of the intrinsic tyrosine-specific protein kinase. The
rapid phosphorylation on tyrosine residues is followed by a
slower serine/threonine phosphorylation of the f3-subunit. Also
prominent in minutes are the changes in activity and phospho-
rylation states of numerous cellular proteins (Fig. 4). Physio-
logically, insulin lowers blood glucose. At the cellular level this
is the" result of the translocation of glucose carriers from an
abundant intracellular pool to the cell surface. Insulin also
causes the internalisation of its receptor and the hormone-
receptor complex enters the cell by endocytosis. It is then
either targeted for degradation or for recycling back to the cell
surface. Elevated circulating levels of insulin increase the rate
of receptor internalisation thus decreasing the numbers of
receptors on the cell surface - a phenomenon referred to as
downregulation. The longer-term effects of insulin include
modulation of DNA and RNA synthesis and increased cell
growth.
Fig. 5. Mechanisms of receptor and post-receptor-mediated
insulin resistance. The mechanisms of post-receptor-mediated
insulin resistance are as yet poorly defined as very liUle is known
about the nature of the post-receptor pathways.
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Mechanisms of insulin resistance
Insulin resistance is said to occur when a physiological concen-
tration of insulin results in a suboptimal effect. This decreased
effect of insulin may be manifested as a rightward shift of the
dose-response curve or a decrease in the maximal response.
The shift in the dose-response curve is referred to as decreased
sensilivily because more hormone is needed to produce the
same effect, while the decrease in maximal response is called
decreased responsiveness. 31 Decreased sensitivity implies a change
in receptor number or affinity, while decreased responsiveness
implies a change in a rate-limiting step, usually at a post-
receptor level. From a clinical standpoint this distinction is
important because decreased sensitivity can be overcome by
increasing the dose of the hormone, whereas with decreased
responsiveness it may not be possible to do this. Aetiologically,
insulin resistance may be the consequence of circulating anta-
gonists or target tissue defects (Fig. 5). Clinical conditions in
which circulating antagonists of insulin are the principal cause
of hyperglycaemia/insulin resistance (i.e. increased catechola-
mines, glucocorticoid excess, acromegaly) are not discussed in
this review as these more commonly manifest as glucose
I
-'I
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Insulin resistance in NIDDM and obesity
Resistance of target tissues to the actions of insulin is a central
feature of NIDDM and is also observed in obesity.32-34 Obese
patients commonly show a decrease in the number of insulin
receptors as a result of the prevailing hyperinsulinaemia
(downregulation). Weight loss results in a reversal of these
changes. Obesity is a common finding in NIDDM and hence
patients with NIDDM also show decreased receptor numbers.
However, even some lean NIDDM patients show decreases in
receptor numbers.
Defects in the receptor kinase
Apart from the changes in receptor numbers in vitro,
euglycaemic clamp studies in vitro indicate that in NIDDM
and in obesity there is decreased sensitivity and responsiveness
implyin~_ife existen~e. ?f both receptor and post-receptor
defects. - The pOSSIbIlIty that these changes may be a con-
sequence of an impairment of receptor-mediated signalling,
i.e. its tyrosine kinase activity, has led to investigations of
receptor kinase activity in both humans and animal models of
NIDDM and obesity. Receptor kinase activity has been found
to be impaired in erythrocytes,35 liver36 and adipose tissue37-40
from obese NIDDM patients. Adipocytes from obese non-
diabetics showed ins].l1in-stimulated kinase activity comparable
to that of normal controls, while obese diabetics showed a 50%
reduction in- kinase activity.40 Although obese non-diabetics
did not show the same defects,40 the defect in obese diabetics
was reversed by weight reduction. Skeletal muscle is quanti-
tatively the most important target tissue for insulin in that it
has a principal role in insulin-stimulated glucose disposal. 41
However, skeletal muscle showed slightly different results in
that kinase activity was impaired by obesity per se, with or
without NIDDM. 42,43 In contrast, autophosphorylation of
muscle receptors from normal, obese and obese diabetic subjects
was the same. The IGF-I receptor was not affected and the
defect appeared to be specific for the insulin receptor. 44
Decreased receptor kinase activity is also seen in animal
models of obesity45,46 but not in other insulin-resistant states.47
The mechanisms of decreased kinase activity observed in all
these studies is uncertain. Tryptic peptide mapping of insulin
receptors from diabetic skeletal muscle showed a decreased
amount of the tris-'phosphorylated peptides that reflects phos-
phorylation of tyrosine residues 1158, 1162 and 1163 and
maximal kinase activation.48 In adipose tissue decreased kinase
activity appeared to be the result of an increased number of
autophosphorylation-incompetent receptors.49 Serine/threonine
phosphorylation of the insulin receptor may regulate the auto-
phosphorylation and hence the kinase activity of these insulin
receptors. In addition, increased internalisation following
hyperinsulinaemia may lead to partial proteolysis of the receptor
and a loss of kinase activity.50
The resistance seen in NIDDM is probably of multifactorial
origin. Numerous factors may operate to create the clinical
features of insulin resistance (Fig. 6). Hyperinsulinaemia per
se, in addition to decreasing receptor numbers, also desensitises
the insulin receptor as a result of uncoupling of the tyrosine
kinase activation from insulin binding.51 Hence, a given con-
centration of insulin action acting on a similar number of
receptors fails to achieve the same level of tyrosine auto-
phosphorylation, kinase activity or cellular effects. The
mechanism of this hyperinsulinism-induced uncoupling is
unknown but does not appear to be related to increased
serine/threonine phosphorylation of the insulin receptor in
cellular models. 51 The initiating defect in the pathogenesis of
insulin resistance in NIDDM is not known, but there appear
to be interrelated events. Chronically elevated insulin levels
lead to a decrease in the number of cell surface receptors
(downregulation). This decrease in cell surface receptors is
accompanied by an attenuation of the insulin-stimulated
tyrosine kinase activity and an increase in the number of
autophosphorylation-incompetent receptors. Additionally, this
is associated with a decrease in the tris-phosphorylated state
that is required for maximal activation of the insulin receptor
kinase. Studies are currently in progress to determine whether
this defective tyrosine kinase activity is associated with
increased serine/threonine phosphorylation of the receptor in
humans and animal models of insulin resistance.
Insulin resistance in NIDDM
defective B cell function .......--- deposition in the pancreas
insllin deficiency !,
~ChrOnJcalIY elevatedgIUCOSe~ Increased Islet amylOid ----_
,
. Increased~nSUllnJProlnsUltn~ ActivalJon of PKC~ I
decreased cell surface receptors (downregulation) unCOUpling of kinase activity
I (desensitization)
, ~ -
~ insulin resistance increased serinelthreonine
!I phosphorylation of the
insulin reeeptor
------------ decreased glucose utilization - ..o--------l
in response to insulin
Fig. 6. Mechanisms of insulin resistance in NIDDM. Insulin resis-
tance in NIDDM appears to be the result of -numerous factors
resulting in both receptor and post-receptor defects (PKC protein
kinase C).
Islet amyloid polypeptide
Another factor that may operate in this scenario is the
presence of elevated levels of islet amyloid polypeptide/
amylin. 52 This recently characterised hormone is co-secreted
with insulin from the B cells of the pancreasY Its precise
function is unknown. However, increased deposition of this
hormone is seen in the pancreata of patients with diabetes
mellitus. 52 In cells and in animal studies, it has been reported
to cause insulin resistance and glucose intolerance.53.54 NIDDM
is associated with increased levels of this hormone (R. Seth, A.
Donaldson and M. W. Makgoba - unpublished data), and ii
has been hypothesised that this may also be responsible for the
insulin resistance seen in NIDDM,52
Glucose transporter defects
As increased glucose uptake is a major action of insulin, it is
possible that defects may arise at the level of the glucose
transporters. Specific glucose carrier proteins facilitate the
transpOrt of glucose into cells. These glucose transpon~rs are
derived from a multigene family of related proteins that are
expressed in a well-defmed tissue-specific marIner-. ~5 Five such
facilitated transpon:ers (designated GLUTl-5 according to the
nomenclature of Bell er al. 55) have been identified from cDNA
clones. 55 In the context of insulin action, the GLUT4 isoform
found in muscle and fat is the most important and mediates
the insulin-stimulated uptake of glucose that occurs post-
prandially.56-59 The GLUT2 (liver) isoform is found in the
pancreatic B cells and may be responsible for sensing changes
in blood glucose.6o Hence defects in these two transporter
proteins could contribute to the pathophysiology of diabetes
mellitus. Other studies suggest that genetic variations in the
GLUTI isoform may be associated with an increased risk of
NIDDM,61 but this has not been confirmed.62.63 .


















Insulin and IGF-I receptor a-l3-subunit dimers may associate
to form 'hybrid' receptors (Fig. 7). Evidence for the existence
of these has been provided by Soos and Siddle82 and Moxham
et al. 83 These partially explain why insulin and IGF-I can
mimic each other's effects on cells.84 The growth-promoting
effects of insulin, seen classically in fetal macrosomia following
diabetic pregnancy, may largely be due to the possibility that
insulin can stimulate growth-promoting pathways by acting
through these hybrid receptors. Furthermore, it indicates that
IGF-II may also exert insulin/IGF-l-Iike effects, presumably
by acting through such receptors as the deduced structure of
the IGF-II receptor indicates that is unlikely to have any
signalling function. Thus hybrid receptors could explain the
occurrence of tumour-associated hypoglycaemia ('specilicity
spillover phenomenon')85 seen with non-islet cell tumours that
produce IGF_II.86.87 Whinaker et al. 88 have suggested that the
hybrid receptors may also explain the effect of negative-
dominant insulin receptor mutations in patients with insulin-
resistant syndromes, i.e. why patients with mutant receptors
and who are simple hyterozygotes should show evidence of
insulin resist~ce. Because the minimal functional unit of the
insulin receptor is a heterotetramer, some mutant a-l3-dimers
may associate with normal a-l3-dimers and impair the sig-
nalling functions of the receptor.
insulin resistance. 77 Most of these antibodies generally inhibit
insulin binding, while some are insulinomimetic. These anti-
bodies may also cause downregulation of the insulin receptor
and hence decrease insulin receptor numbers at the cell surface.
Some patients with NIDDM78 or newly diagnosed IDDM79
develop ldw titres of auto-antibodies that arise partly as anti-
idiotypes of anti-insulin antibodies.8o,81
Conclusions
Fig. 7. Hybrid insulinllGF-1 receptors. IGF-I receptors are
remarkably similar to insulin receptors in their gross structural
organisation, size, amino acid sequence and function. Receptor
subunit dimers may dissociate under suitable redox conditions
and reassemble with dimers from the heterologous receptor.
Alternatively, the assembly of hybrids may occur during synthesis
of the respective receptors. IGF-II mediates its biological effects
through its heterologous relatives.
Adipocytes and muscle cells from diabetic animals show a
marked decrease in insulin-stimulated glucose uptake owing to
a decrease in the number of glucose transporters at the cell
surface.64.65 Impaired insulin action in adipocytes from diabetic
animals is associated with a decrease in the level of expression
of the insulin-stimulated GLUT4 isoform. In diabetic humans,
studies on adipocytes have described a decrease in whole cell
glucose transport as a result of defects in the number and
function of glucose transporters.55
Extreme insulin resistance
In humans extreme or severe insulin resistance is seen in the
context of several congenital syndromes including the type A
syndrome, leprechaunism and lipo-atrophic diabetes (for
reviews see references 66 and 67). Although distinctly rare and
diverse, studies in patients with these conditions have provided
some insight into the structure and function of the insulin
receptor. This extreme iI).sulin resistance may be the result of
markedl~ decreased insulin binding and/or receptor kinase
activity. 8-71 The decrease in binding is usually the result of
decreased numbers of cell surface receptors. The autophos-
phorylation and kinase activity of monocyte insulin receptors
from a patient with the type A syndrome72 was decreased by
90% in comparision with normal controls. This occurred in the
presence of normal insulin binding affinity. Erythrocytes and
fibroblasts from other type A patients showed similar, though
less severe, impairment of kinase activity.68,69 Insulin receptors
from fibroblasts, hepatocytes and lymphocytes of a lipodystro-
phic patient also showed decreased kinase activity.71 Although
these studies support an association between defects in kinase
activity and severe insulin resistance, impaired kinase activity
is not observed in all subjects with extreme insulin resis-
72-74tance.
The availability of the human insulin receptor cDNA coupled
with the polymerase chain reaction has made it possible to
examine the nucleotide sequence of the insulin receptor in
several such patients. Mutations have been identified in both
subunits of the insulin receptor (reviewed in reference 75).
Some of these (e.g. Arg909_ stop codon) (residue numbers
according to the deduced sequence of Ebina et al.8 ) affect the
synthesis of the insulin receptor mRNA and manifest as a
decreased number of cell surface receptors in binding studies.
Others (Phe382- Val) affect the transport of the receptor to the
cell surface after synthesis. The first mutation described took
the form of Arg747- Ser within the tetrabasic cleavage region.
This resulted in uncleaved precursor with decreased binding
affmity being inserted into the plasma membrane. Further
mutations decrease the binding function of the, receptor
Leu233- Pro) or its kinase' activity (GlyI020- Vall; Trp1212_
Ser). One particular mutation (Lys460_ Glu) actually increases
the binding afImity of the receptor. However, because this
results in accelerated downregulation and preferential degra-
dation of the insulin receptor, insulin resistance occurs. In
general, mutations in the extracellular regions of the receptor
affect the binding of insulin whereas intracellular mutations
result in decreased kinase activity.
The contribution of receptor gene mutations to the insulin
resistance of NIDDM is as yet unclear, although studies are
underway to evaluate this aspect.76 It is possible that some
receptor gene mutations may not be severe or extensive enough
to cause a full-blown syndrome of extreme insulin resistance,
and may instead manifest in the milder insulin resistance of
NIDDM.
Auto-antibodies
Auto-antibodies to the insulin receptor may also cause
insulin resistance as part of the type B syndrome of extreme
While the precise molecular mechanism of insulin action
continues to be a mystery, various pieces are slowly being
added to the puzzle. Over the next few years much anention
will be devoted towards defming the immediate post-receptor
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events. It will be imponant to elucidate the links between
receptor activation and glucose transpon. This will involve
isolation of the enzymes involved and eventual molecular
cloning. Particular effort is being devoted towards isolating
cellular substrates for the insulin receptor as it is essentially an
enzyme. Recent advances in recombinant DNA technology,
particularly the polymerase chain reaction, have made it pos-
sible to investigate patients for mutations in the insulin receptor
or the glucose transporters. It is by anempting to solve the
questions regarding insulin and insulin receptor function at
the molecular level that it will be possible to understand the
pathophysiology of insulin resistance.
T.S.P. was a recipient of the Emanuel Bradlow Scholarship
from the Bradlow Foundation. Pans of this work were supponed
by a Hammersmith and Queen Charlones Special. Health Authority
grant for locally organised research. M.W.M. is supponed by the
British Medical Research Council.
Addendum
It has recently been demonstrated that fibroblasts from a
patient with insulin resistance and NIDDM produce a glyco-
protein inhibitor of insulin receptor kinase activity (Sbracchia,
P, Goodman PA, Maddux BA et al. Diabetes 1991; 40: 295-299).
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